The aims of this review were: the evaluation of the benefits and harms of long-term therapy with an RAI compared with short-acting human insulin, as well as; the evaluation of the benefits and harms of RAIs compared with each other, in each case in patients with diabetes mellitus type 1. The focus of the evaluation was on patient-relevant therapy goals (in particular, morbidity, mortality, quality of life, and adverse events). All RAIs approved and available in Germany at the time of report production were evaluated (insulin aspart, insulin glulisine, and insulin lispro). The evaluation was conducted on the basis of the comparison and weighing of desired and undesired effects of the individual drugs (weighing of benefits and harms).
评估与短效人胰岛素相比，赖脯胰岛素类似物（RAI）长期治疗的益处和危害；以及评估在1型糖尿病患者中，不同RAI之间的益处和危害。评估重点在于与患者相关的治疗目标（特别是发病率、死亡率、生活质量和不良事件）。对报告撰写时在德国已获批并可获得的所有RAI（门冬胰岛素、谷赖胰岛素和赖脯胰岛素）进行了评估。评估是在比较和权衡每种药物的预期和非预期效果（权衡利弊）的基础上进行的。
